Search results
Results From The WOW.Com Content Network
Throughout the 1960s, concerns raised about the proliferation of unauthorized use of psychedelic drugs by the general public (and, most notably, the counterculture) resulted in the imposition of increasingly severe restrictions on medical and psychiatric research conducted with psychedelic substances. [26]
Psychedelic therapy (or psychedelic-assisted therapy) is the proposed use of psychedelic drugs to treat mental disorders. [59] As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions. [34] [60]
Psychedelic therapy involves the use of a hallucinogenic, perception-altering drugs coupled with psychotherapy to treat patients psychologically. The goal of the procedure was to unearth internal conflicts by administering LSD and then use therapy to resolve and work through these emerging latent conflicts.
It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug.
Psychedelic therapy (or psychedelic-assisted therapy) refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, [note 2] LSD, and ayahuasca, to treat mental disorders. [ 58 ] [ 59 ] As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials ...
Psychedelic treatments for trauma-related disorders are the use of psychedelic substances, either alone or used in conjunction with psychotherapy, to treat trauma-related disorders. [1] Trauma-related disorders, such as post-traumatic stress disorder (PTSD), have a lifetime prevalence of around 8% in the US population. [ 2 ]
The Journal of Psychoactive Drugs is a peer-reviewed medical journal on psychoactive drugs. It was established in 1967 by David E. Smith and is currently published five times per year by Taylor & Francis. It was previously titled Journal of Psychedelic Drugs until 1980.
Interest in the drugs tended to focus on either the potential for psychotherapeutic applications of the drugs (see psychedelic psychotherapy), or on the use of hallucinogens to produce a "controlled psychosis", in order to understand psychotic disorders such as schizophrenia. By 1951, more than 100 articles on LSD had appeared in medical ...